Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nevirapine
Drug ID BADD_D01557
Description A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Indications and Usage For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Marketing Status approved
ATC Code J05AG01
DrugBank ID DB00238
KEGG ID D00435
MeSH ID D019829
PubChem ID 4463
TTD Drug ID D0O2EM
NDC Product Code 53104-7546; 70159-002; 65862-027; 0378-4050; 64380-709; 65862-932; 65862-933; 31722-505; 65862-057; 68554-0044; 33342-004; 0597-0047; 64220-102; 0378-4890; 65162-209; 33342-238; 42571-131
UNII 99DK7FVK1H
Synonyms Nevirapine | Nevirapine Hemihydrate | Hemihydrate, Nevirapine | Viramune | BI-RG-587 | BI RG 587 | BIRG587
Chemical Information
Molecular Formula C15H14N4O
CAS Registry Number 129618-40-2
SMILES CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.002652%
Abdominal pain07.01.05.002--
Abortion spontaneous18.01.04.0010.005304%-
Acute myocardial infarction02.02.02.001; 24.04.04.0010.007956%-
Agranulocytosis01.02.03.001---
Alanine aminotransferase13.03.04.002---
Alanine aminotransferase abnormal13.03.04.003---
Alanine aminotransferase increased13.03.04.005--
Anaemia01.03.02.0010.006630%
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Angina pectoris02.02.02.002; 24.04.04.0020.003978%
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Arthralgia15.01.02.001--
Aspartate aminotransferase13.03.04.008---
Aspartate aminotransferase abnormal13.03.04.009---
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001---
Blister12.01.06.002; 23.03.01.001---
Blood bilirubin13.03.04.015---
Blood pressure increased13.14.03.005---
Blood triglycerides increased13.12.03.001---
Body temperature increased13.15.01.001---
Bone disorder15.02.04.004---
Breast enlargement21.05.04.001---
Cardiac failure congestive02.05.01.0020.006630%-
Cerebrovascular accident17.08.01.007; 24.03.05.0010.007956%
Cholestasis09.01.01.0010.003978%-
Chronic hepatitis B09.01.09.008; 11.05.28.001---
Condition aggravated08.01.03.0040.005304%-
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene